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http://www.trialsjournal.com/content/14/1/299STUDY PROTOCOL Open AccessVitamin D supplementation in older people
(VDOP): Study protocol for a randomised
controlled intervention trial with monthly oral
dosing with 12,000 IU, 24,000 IU or 48,000 IU of
vitamin D3
Inez Schoenmakers1*, Roger M Francis2, Elaine McColl3, Thomas Chadwick4, Gail R Goldberg1, Christine Harle3,
Alison Yarnall2,5, Jennifer Wilkinson3, Jennie Parker3, Ann Prentice1 and Terence Aspray2,5Abstract
The randomised, double blind intervention trial ‘Optimising Vitamin D Status in Older People’ (VDOP) will test the
effect of three oral dosages of vitamin D given for one year on bone mineral density (BMD) and biochemical
markers of vitamin D metabolism, bone turnover and safety in older people. VDOP is funded by Arthritis Research
UK, supported through Newcastle University and MRC Human Nutrition Research and sponsored by the Newcastle
upon Tyne Hospitals NHS Foundation Trust.a
Background: Vitamin D insufficiency is common in older people and may lead to secondary hyperparathyroidism,
bone loss, impairment of muscle function and increased risk of falls and fractures. Vitamin D supplementation trials
have yielded conflicting results with regard to decreasing rates of bone loss, falls and fractures and the optimal
plasma concentration of 25 hydroxy vitamin D (25OHD) for skeletal health remains unclear.
Method/design: Older (≥70 years) community dwelling men and women are recruited through General Practices
in Northern England and 375 participants are randomised to take 12,000 international units (IU), 24,000 IU or 48,000
IU of vitamin D3 orally each month for one year starting in the winter or early spring. Hip BMD and anthropometry
are measured at baseline and 12 months. Fasting blood samples are collected at baseline and three-month
intervals for the measurement of plasma 25OHD, parathyroid hormone (PTH), biochemical markers of bone turnover
and biochemistry to assess the dose–response and safety of supplementation. Questionnaire data include falls,
fractures, quality of life, adverse events and outcomes, compliance, dietary calcium intake and sunshine exposure.
Discussion: This is the first integrated vitamin D supplementation trial in older men and women using a range of doses
given at monthly intervals to assess BMD, plasma 25OHD, PTH and biochemical markers of bone turnover and safety,
quality of life and physical performance. We aim to investigate the vitamin D supplementation and plasma 25OHD
concentration required to maintain bone health and to develop a set of biochemical markers that reflects the effect of
vitamin D on bone. This will aid future studies investigating the effect of vitamin D supplementation on fracture risk.
#ISRCTN 35648481 (assigned 16 August 2012), EudraCT 2011-004890-10.
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Vitamin D status and musculoskeletal health
Vitamin D insufficiency is common in older people and
may lead to increased bone resorption, bone loss, im-
pairment of muscle function and an increased risk of
falls and fractures. The results of clinical trials assessing
the effect of vitamin D supplementation on bone loss,
falls and fractures have yielded conflicting results and
the blood concentration of 25 hydroxy vitamin D
(25OHD) required to maintain optimal skeletal health
remains unclear. Unfortunately, there is no universal
consensus on the optimal way of assessing vitamin D
status or on what constitutes vitamin D repletion at dif-
ferent ages throughout life [1].
Vitamin D status is currently assessed by measurement
of plasma 25OHD concentration. In the UK, vitamin D
deficiency has been defined as a plasma 25OHD less
than 25 nmol/L, the upper end of the range at which
vitamin D deficiency osteomalacia and rickets have
been observed [2,3]. Recent epidemiological and cross-
sectional studies have shown that 25OHD concentra-
tions above 25 nmol/L may also be associated with
secondary hyperparathyroidism, higher bone resorption,
bone loss, impaired muscle function and a greater risk
of falls and fragility fractures [4-8] when compared to
concentrations of 40 to 75 nmol/L and above.Vitamin D status and requirements
A plasma 25OHD concentration of 40 to 50 nmol/L has
been suggested as a cut-off for vitamin D insufficiency
[2,9-11]. However, some experts have advocated higher
concentrations of 25OHD (75 to 150 nmol/L) for the
maintenance of bone health and other non-skeletal ben-
efits [12-17]. Few individuals in the UK achieve these con-
centrations of 25OHD in winter and spring, when more
than 80% of 45-year-old men and women have a plasma
25OHD concentration less than 75 nmol/L [18-20]. Vita-
min D status is poorer in older people, where approxi-
mately 12% of people living in private households and 30%
of care home residents have a plasma 25OHD concentra-
tion below 25 nmol/L throughout the year, reflecting their
reduced exposure to sunlight, low dietary intake of vita-
min D and potentially their higher expenditure of vitamin
D [14,18,21].
The dietary Reference Nutrient Intake (RNI) for vita-
min D in the UK for people over 65 years is currently
400 International Units (IU) (= 10 μg) per day. In the
US, the Estimated Average Requirement (EAR) and
Recommended Dietary Allowance (RDA) for those over
70 years of age is 600 (15 μg) and 800 IU (20 μg) per
day, respectively [11,22]. It is recognised that supple-
mentation is generally necessary to achieve these intakes
[23]. Despite this advice, vitamin D supplementation isuncommon in older people, even in care home residents
[18,24-26].
Vitamin D supplementation and fracture risk
Several placebo-controlled intervention trials have exam-
ined the effect of vitamin D supplementation on fracture
risk. Some meta-analyses suggest that vitamin D supple-
mentation doses of 800 to 1000 IU daily decrease the in-
cidence of falls and fractures in older women, whereas
lower doses are ineffective [27-29]. In contrast, other
meta-analyses, including the latest Cochrane Review [30],
indicate that vitamin D supplementation does not de-
crease fracture risk, unless combined with calcium, when
it reduces the risk of hip and other non-vertebral fractures
in care home residents [31,32]. One randomised con-
trolled trial of a single annual oral dose of 500,000 IU
vitamin D showed an increase in falls and fractures, par-
ticularly in the first three months after administration
[33]. Other studies using 300,000 or 600,000 IU per
annum have shown mixed results: 100,000 IU adminis-
tered at four-month intervals was associated with a de-
crease in fracture risk, whereas 300,000 IU of vitamin D2
by i.m. injection or 150,000 IU administered orally every
three months was associated with no benefit [34-36].
These results suggest that not only the dose but also the
frequency of administration may determine the risk and
benefit for falls and fractures. The mechanisms of this
association remain unclear and are likely to be multi-
factorial.
The evidence for the effects of vitamin D supplemen-
tation on BMD or the prevention of bone loss in older
people is conflicting [37,38]. The differences in the
reported efficacy of vitamin D may be because the dose
of vitamin D in several trials may have been too low or
compliance and persistence with supplementation may
have been poor, resulting in a failure to achieve a high
enough plasma 25OHD to reduce bone loss and obtain
an anti-fracture benefit [13,39-41]. Alternatively, the par-
ticipants in some trials may have been vitamin D replete
[41], even if their baseline plasma 25OHD concentra-
tions were lower than those advocated by North
American experts [12,15,16]. Moreover, differences in
reported efficacy may have been due to differences in
the study population, the dose of vitamin D, the route
and frequency of administration and/or the use of differ-
ent forms of vitamin D (vitamin D2 and vitamin D3).
Several studies have indicated that the achieved plasma
25OHD concentration, rather than the vitamin D dose
given, predicts the effect on bone health [42]. However,
measurement of plasma 25OHD, parathyroid hormone
(PTH) and other potential markers of vitamin D status
have only been performed in a small minority of partici-
pants in these intervention studies [41], limiting the abil-
ity to explore the relationship between plasma 25OHD
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Vitamin D status markers for bone health
Before performing further studies of the effect of vitamin
D supplementation on the risk of major outcomes such as
fragility fractures or cardiovascular disease [12,13,43,44],
there is a need to understand better the relationship be-
tween vitamin D intake, plasma 25OHD and bone health
in older people and to develop better functional markers
of vitamin D status, reflecting vitamin D function at the
level of the target organ [3,45]. These functional markers
will be instrumental in establishing clearer criteria for vita-
min D sufficiency and insufficiency and help to clarify the
optimal dose and frequency of vitamin D supplementa-
tion. Potential markers of vitamin D status have been
reviewed [3]. Plasma PTH has been proposed as a func-
tional marker, because an elevated concentration is a
recognised risk factor for bone loss and fractures in older
people [6-9,13,46-48], which can potentially be modified
by vitamin D supplementation [49,50]. The circulating
concentration of 25OHD below which PTH increases out-
side the normal range may be used to establish a threshold
value for vitamin D insufficiency [1]. However, PTH varies
within and between people at any given concentration of
25OHD [18,51], as PTH depends on many factors other
than vitamin D status [52]. These include stage of life, eth-
nic background, dietary calcium and phosphate intake,
time of day, renal function, serum magnesium, physical in-
activity and medication use [3,14,53-55].
Aim
The Optimising Vitamin D Status in Older People
(VDOP) trial aims to examine the relationship between
vitamin D supplementation at a range of doses and the
change in bone mineral density (BMD) in older people
living in private households in the North East of
England. Vitamin D3 supplementation is given orally
each month, for a year (12,000 IU/month, 24,000 IU/
month or 48,000 IU/month, equivalent to 400 IU/day,
800 IU/day and 1,600 IU/day, respectively). We will ex-
plore the relationship between the change in BMD and
the achieved plasma 25OHD and PTH over 12 months.
As BMD is the result of the balance between bone for-
mation and resorption, the effect of the supplement on
the change in markers of bone turnover will be explored.
Plasma C-terminal telopeptide (CTX), bone specific
alkaline phosphatase (bone ALP) and N-terminal
propeptide of procollagen type I (P1NP) will be mea-
sured, as it has been suggested that these may be the
best surrogate bone turnover markers for the effect of
pharmacological intervention on fracture incidence [56].
We will also investigate the effect of duration of treat-
ment and season on the dose–response.Rationale for dosage and dosing regimen
Two of the dosages applied in this trial correspond to
the current Scientific Advisory Committee on Nutrition
(SACN) RNI (400 IU/day) and the Institute of Medicine
(IOM) RDA (800 IU/day) for this age group [2,11]. The
highest dose is twice the IOM RDA and well below the
IOM Tolerable Upper Intake Level (TUIL) defined by
the IOM (4,000 IU/day) [11].
This trial uses a monthly dosage scheme as this is
expected to result in improved compliance compared to
daily or weekly dosages [57]. Compliance will be encour-
aged through administration of the dose under direct
supervision on four occasions and taking the other doses
will be prompted by telephone calls by staff from the re-
search centre.
Methods/design
Study design
The VDOP trial is a single centre parallel group,
randomised, double blind interventional trial testing the ef-
fects of three dosages of oral vitamin D3 given each month
to men and women 70 years old and older for a year. The
primary outcome is the change in BMD at the hip (total
hip BMD) from baseline to 12 months post intervention.
Recruitment
Community dwelling men and women 70-years-old and
older, are recruited through General Practices (GP) in
Tyneside, Wearside and Northumberland, participating
in the Northern and Yorkshire Primary Care Research
Network (PCRN-NY). Potentially eligible participants
are identified from GP practice registers, after initial
screening against inclusion and exclusion criteria on
electronic medical records. An invitation letter is sent to
potential participants, including details of the study and
a pre-paid response slip. Those expressing an interest
are contacted by the research team, further screening
performed to ensure that the participant is eligible and
an invitation to participate is then offered, after any dis-
cussions the potential participant might wish. If still in-
terested, an appointment is made for the first study visit,
when written informed consent is obtained, and a blood
sample is collected to perform the final assessment of
eligibility (screening for biochemical exclusion criteria:
see below). If eligible, baseline visit measurements and
questionnaires are completed.
Inclusion criteria
Inclusion criteria are as follows:
1. Ambulatory, community dwelling men and women
70 years old and older
2. Individuals capable of giving informed consent on
their own behalf
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(The Clinical Ageing Research Unit (CARU)) on six
occasions and to be contacted by telephone at monthly
intervals between study visits over twelve monthsExclusion criteria
Exclusion criteria are as follows:
1. Current antiresorptive or anabolic treatment for
osteoporosis
2. Treatment with bisphosphonates for osteoporosis in
the past two years
3. Current supplement use of vitamin D (>400 IU/day)
or calcium (>500 mg/day) (including use of over-
the-counter preparations)
4. Fragility fracture in the previous six months
5. Known primary hyperparathyroidism
6. History of renal stones
7. Hip replacement
Biochemical:
1. Hypercalcaemia (albumin-adjusted serum calcium
>2.60 mmol/L)
2. Renal impairment (Stage 4 or 5 Chronic Kidney
Disease: estimated glomerular filtration rate (eGFR)
below 30 ml/min/1.73m2 calculated using the
modification of diet in renal disease (MDRD)
formula.
There will be no limits to concomitant care or medica-
tion use other than defined in the inclusion and
exclusion criteria. Participation in the VDOP trial is
discontinued when during the course of the trial condi-
tions develop where vitamin D supplementation is
contra-indicated.Randomisation, Investigational Medicinal Product (IMP)
and IMP administration
Participants are randomised using a computerised sys-
tem in a 1:1:1 ratio to three treatment arms (12,000 IU,
24,000 IU or 48,000 IU vitamin D3 once monthly for 12
months) by a statistician within the Newcastle Clinical
Trials Unit (CTU) not otherwise engaged in the study.
Permuted blocks of variable length are used to reduce
the risk of breach of concealment of allocation.
Allocation lists are provided to Apotek Produktion &
Laboratorier AB (APL; Stockholm, Sweden) which pro-
duces numbered packs of the Investigational Medicinal
Product (IMP) per participant for shipping to the
Newcastle upon Tyne Hospitals NHS Foundation Trust
pharmacy for dispensing. The allocation is not stratified
and allocation status is kept concealed from participantand research staff unless code break is required for
safety reasons.
The IMP is composed of vitamin D3 dissolved in
Miglyol as Vigantol® (Merck Sereno GmbH, Darmstadt
Germany). One ml of Vigantol® solution contains 0.5 mg
cholecalciferol, equivalent to 20,000 IU vitamin D3. Blin-
ding of Vigantol® oil across the three doses (12,000 IU,
24,000 IU and 48,000 IU) is achieved by further dilution,
using Miglyol® 812 oil (Sasol; The Warner Graham
Company, Cockeysville, MD USA) and the stabilising
agent butylhydroxianisole, both free of vitamin D3. For
the highest dose, only the stabilising agent is added. All
three doses of vitamin D are dispensed in 10 ml amber
glass bottles (target fill volume of 3 ml including 0.6 ml
overage).
MODEPHARMA (London, UK) is responsible for
arranging the manufacture of the IMP and project
management and assistance relating to the IMP. The
formulation, manufacture and release of the IMP is
undertaken by APL, a Swedish clinical supplies company
licensed for the manufacture and release of IMPs for
clinical trial use in the EU.
The IMP is administered orally under direct supervi-
sion of a research nurse at baseline and at the third,
sixth and ninth month study visits. At the end of each
study visit, participants are given two bottles of the study
IMP for the two subsequent months before their next
scheduled visit to CARU, together with written instruc-
tions on how to take the IMP. On months when the par-
ticipant is not attending the clinic, they are contacted by
telephone, to remind them to take the IMP. Participants
are directed to return all IMP bottles in their original
packaging to the research team. Researchers return these
to the trial pharmacist and all returned or unused study
IMPs are documented in the Pharmacy File and then
destroyed according to Pharmacy Standard Operating
Procedures.
Measurements
An overview of the timing of measurements, sample col-
lections and data collection is given in Table 1. Total hip
BMD is measured using Dual-Energy X-ray Absorpti-
ometry (DXA) (i-Lunar DXa, GE Healthcare, Madison
Wisconsin USA) at baseline and 12 months. The densi-
tometer is calibrated daily prior to participant scanning.
The total radiation dose (0.04 mSv) is equivalent to
having a chest X-ray. Height and weight, demispan,
waist-hip ratio and the Timed Up and Go (TU&G) test
are determined [58] and the participant’s medical history
(including medication and supplement use) reviewed. A
standardised physical exam including the assessment of
vital signs, blood pressure, and questionnaires assessing
bone pain, fracture risk and falls history are performed
(adapted from standard clinical care questions and the
Table 1 Schedule of study procedures for VDOP
Phone call 0 Visit 0 Visit 1 Phone
call 1
Phone
call 2
Visit 2 Phone
call 3
Phone
call 4
Visit 3 Phone
call 5
Phone
call 6
Visit 4 Phone
call 7
Phone
call 8
Visit 5
Pre- Screening Pre- Screening Screening Baseline visit FUPa 1 FUPa 2 FUPa 3 FUPa 4 FUPa 5 FUPa 6 FUPa 7 FUPa 8 FUPa 9 FUPa 10 FUPa 11 Final visit
Venue PICa Home CARUa CARUa Home Home CARUa Home Home CARUa Home Home CARUa Home Home CARUa
Month −1 0 0 0 1 2 3 4 5 6 7 8 9 10 11 12
Identification X
Pre-Screening X
Informed consent X
Venipuncture
(screening)
X
Randomisation X
Medical history,
Demispan,,
falls history and
fracture risk
X
Demographics X
TU&Ga test grip
strength
X X
DXA (total hip)
weight height
X X
Venipuncture
(safety
and
biochemistry)
X X X X X
Urine sample X X X X X
Physical exam
and vital signs
X X X X X
Quality of Life X X X X X
CalQuest X X X
Sunshine
exposure
X X X X X
Falls diaries ———————— ———————— —————➔ X ——————— —————➔ X ——————— —————➔ X ——————— —————➔ X
Administer
treatment
X X X X X X X X X X X X
Check drug
adherence
X X X X X X X X X X X X
aCARU Clinical Ageing Research Unit, FUP follow-up visit, PIC Patient Identification Centre, TU&G Time up and Go.
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timed urine samples are collected after an overnight fast
between 8:30 and 11:30 AM. After venipuncture, partici-
pants are offered breakfast. Questionnaires are used to col-
lect data on demographics, quality of life (WHOQol-BREF
UK version and UK WHOQOL-old; [60,61]), dietary cal-
cium and vitamin D intake (adapted from Calquest; [62])
and sunshine exposure in the UK and during overseas
travel (adapted from [63]). Participants are also asked to
keep a three-month prospective falls diary. At each
visit, information is collected on participant-reported
adverse events (AEs), serious adverse events (SAEs)
and suspected unexpected serious adverse reactions
(SUSARs). In addition, at every visit, safety is assessed
specifically by performing full blood count, serum al-
bumin adjusted calcium, creatinine and liver function.
Information on clinical fractures during the study is
recorded as a safety measure.
Biochemical analyses
Blood samples are collected into tubes containing
ethylenediaminetetraacetic acid (EDTA), lithium heparin
(LH) or serum-separation gel (BD Diagnostics, Oxford,
UK) and one EDTA and one LH tube is immediately
placed on ice. Samples for clinical biochemistry and safety
measurements are sent to Newcastle upon Tyne hospitals
NHS Foundation Trust (NUTH) laboratories and analysed
immediately. These include eGFR, full blood count
(FBC), urea and electrolytes (U&E) and liver function
tests (LFT) which include: serum sodium, potassium,
urea, total protein, total bilirubin, alanine transaminase,
calcium, phosphate, magnesium, albumin, alkaline phos-
phatase (ALP) and creatinine. The remaining blood
samples are separated within 30 minutes of collection
in a refrigerated centrifuge at 1,800 g for 20 minutes
and stored at −80°C prior to analysis at MRC Human
Nutrition Research, Cambridge, UK. Blood pellets are
stored at −20°C for potential genetic analyses. Collected
urine is mixed thoroughly and aliquots are analysed for
calcium, phosphate and creatinine (Cr) immediately at
NUTH laboratories.
All assays are performed in duplicate with the exception
of PTH. EDTA plasma is used for analysis of PTH by im-
munoassay (Immulite, Siemens Healthcare Diagnostics Ltd,
Camberley, UK). LH plasma is used for the measurement
of 25OHD, BAP (both DiaSorin-Liaison, Stillwater, Mn,
USA) and CTX (IDS Ltd, Tyne and Wear, UK) according
to standardised protocols [64]). Assay performance is moni-
tored using kit and in-house controls and under strict
standardisation according to ISO 9001:2000. Quality assur-
ance of 25OHD and PTH assays are performed as part of
the Vitamin D External Quality Assessment Scheme (www.
deqas.org), and the National External Quality Assessment
Scheme (www.ukneqas.org.uk).Data entry and analyses of questionnaires
An electronic case report form (eCRF) is created for each
participant using a standardised computerised system
(InferMed’s MACRO) at CTU. Biochemistry data are gen-
erated electronically and collated in a standardised format.
Dietary contents of calcium and vitamin D are derived
from food tables. Quality checks of data entry and mer-
ging are performed.
Sample size and power calculation
The sample size calculation was based on an unpaired
two-group comparison of the absolute change in BMD
at the hip within individual participants over the 12
months of the study. This illustrates the power for a pri-
mary comparison of interest between any two chosen
arms in the three-arm design of this study; given the
choices detailed below, the calculations would be identi-
cal for any selected pair of arms. Absolute change is
used, rather than percentage change, as it is statistically
more efficient [65].
Data from a population based study [50] showed that
standard deviation (SD) in absolute change of BMD at
the hip over 12 months in women 60 to 70 years old, liv-
ing in Aberdeen, is between 0.012 and 0.015 after sup-
plementation with a placebo or two vitamin D dosages
(0, 400 IU and 1,000 IU). As this SD is relatively stable
in value but does not include values for two of our three
dosage levels, the conservative choice was made to use the
largest SD estimate and to apply the two-sample t-test, a
two-sided significance level of 0.05 and a power of 80% in
the calculations. Aiming to be able to detect a difference of
0.006 g/cm2 (equivalent to a moderate standardised effect
size of 0.4) between two arms, 100 participants per arm
would be needed. Making an allowance for 20% attrition at
the 12 month follow-up results in 125 participants per arm
(375 in total) being required. This sample size would give
90% power to detect a difference of 0.007 g/cm2 between a
pair of arms. We believe that a difference in BMD of the
order of 0.006 g/cm2 against the background of the antici-
pated yearly decrease in BMD in an untreated population
would be clinically significant [50].
Statistical analyses
The primary outcome of this study is the 12 month
change in BMD at the hip (total hip BMD).
The secondary outcome measures are the changes in
plasma 25OHD concentration and PTH, so as to explore
their use as functional markers in relation to change in
BMD and biochemical markers of bone turnover. Data
are also being obtained on the proportion of participants
in each treatment group who fall, the number of falls,
quality of life and safety.
Analyses are performed according to a formal pre-
planned documented analysis plan. Analysis will be carried
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exploratory analyses may also be considered. There are no
planned interim analyses.
Data with missing observations due to loss to follow-
up will be examined to determine both the extent of
missingness and whether it is missing at random or is
selective. If data are missing to a sufficient extent, the
use of appropriate multiple imputation techniques will
be considered to allow for this in the analysis.
Analysis of the primary outcome measure (12 month
change in BMD at the hip) will be performed using
Analysis of Covariance (ANCOVA) to compare the re-
sponse in the three treatment groups while allowing for
the effects of covariates. Baseline BMD at the hip, PTH
and 25OHD measures will be included in addition to
measures of kidney function, BMI, gender and age. In-
teractions will also be explored. The inclusion of base-
line values as covariates will also enable the examination
of possible interactions between effects observed and
these values.
A number of secondary analyses will also be under-
taken. Alternative clinical indicators (such as change in
plasma 25OHD, PTH, falls, physical performance, qual-
ity of life measures and other biochemical markers) will
be compared between the three treatment groups, using
similar techniques to those described above.
The relationship of PTH as a dependent variable with
25OHD and kidney function as independent variables
will be examined using regression methods. Further ex-
ploratory regression models will explore the relation-
ships of 25OHD and PTH with change in BMD and
biochemical markers of bone turnover. The relationship
between 25OHD and BMI will also be explored using
similar regression methods.
The relationship of 25OHD at different time points as
a dependent variable, with season and duration of sup-
plementation as independent variables, will be examined
using regression or repeated measures methods.
Ethical considerations
This study has received a favourable opinion from the
Sunderland Research Ethics Committee (REC, 12/NE/
0050) and R and D approval from the Newcastle upon
Tyne Hospitals NHS Foundation Trust (sponsor). The
conduct of this study is in accordance with the recom-
mendations for physicians involved in research on human
subjects adopted by the 18th World Medical Assembly,
Helsinki 1964 and later revisions.
The study involves procedures that may be unfamiliar
to participants and are not part of their standard medical
care. These procedures are explained in information
sheets provided to all potential participants prior to their
screening visit and written informed consent is obtained
prior to any study procedures. The consent formspecifies the separate study components and includes an
opt in/opt out section for genetic analyses and permis-
sion to be approached for potential affiliated studies.
Participants who lack capacity to consent for themselves
are excluded from this study. In the unlikely event that a
participant loses capacity after they have provided con-
sent to take part, their case will be reviewed by the Chief
Investigator and the legal representative of the partici-
pant to decide whether to continue in the study.
The hip BMD DXA measurement involves a low dose
of radiation (see measurements).
The latest Cochrane Review suggests that vitamin D
supplementation may be associated with a small increased
risk of gastrointestinal side effects, hypercalcaemia, renal
stones and renal impairment, particularly when given with
additional calcium or when active metabolites of vitamin
D are used [32]. However, the doses to be used in this
study are not generally associated with adverse events
[11,22]. As we are using vitamin D alone, without add-
itional calcium supplementation, we do not anticipate that
this will pose a significant risk to participants. The highest
dose of vitamin D3 used in this study is less than half the
TUIL recently advised by the IOM [11,22].
Reporting and evaluation of adverse events, serious
adverse events and suspected unexpected serious
adverse reactions
The development or progression of age-related medical
conditions is anticipated to occur spontaneously during
the study. On the basis of the latest Cochrane Review a
small increased risk of side effects may be expected (see
above). Any AEs, SAEs or SUSARs are verified against
treatment notes/medical records and causality assessed
using standard criteria according to Good Clinical Practice
(GCP) guidelines [66]. All adverse events judged by the
Trial Steering Committee (TSG) as having a reasonable
suspected causal relationship to the IMP are considered to
be adverse reactions and are reported to the sponsor, the
Medicines and Healthcare products Regulatory Agency
(MHRA) and REC in accordance with current legislation.
Data protection
Data are handled, computerised and stored in accord-
ance with the Data Protection Act 1998, guidelines for
GCP [66,67] and local policy. Data collected on paper
are entered on a secure validated clinical data manage-
ment system (InferMed’s MACRO). No participant identi-
fiable data will leave the study site. To preserve anonymity,
any data or samples leaving the site will identify partici-
pants by a unique study identification code (linked in
anonymised form). All identifiable study records and
Investigator Site Files are kept at the site in a locked
filing cabinet with restricted access and on encrypted
and/or pass-word protected computers.
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The daily management lies with the Trial Management
Group (TMG) which comprises Dr Terry Aspray
(Chief Investigator (Chair)), Professor Roger Francis
(Co-Investigator), Dr Tom Chadwick (Statistician),
Dr Jennifer Wilkinson (Senior Trial Manager), Christine
Harle (Trial Manager), Jennie Parker (Assistant Trial
Manager), Ian Campbell (Assistant Director of Pharmacy)
and Katie Argo (Clinical Trials Pharmacist). The UK
CRC registered Newcastle Clinical Trials Unit (NCTU)
has delegated authority from the sponsor for obtaining
ethical and regulatory approvals, trial management and
ensuring that the study is conducted in accordance with
the principles of GCP and pharmacovigilance.
The TSG consists of the TMG and Professor David
Reid (Independent Chair), Professor Elaine McColl (Co-
investigator), Dr Gail Goldberg (Co-investigator), Dr Ann
Prentice (Co-investigator), Dr Inez Schoenmakers (Co-
investigator), Dr Elina Hypponen (Independent member),
Professor Sue Lanham-New (Independent member) and
two Lay members (Patient support group representatives).
The Data Monitoring and Ethics Committee (DMEC)
comprises Professor Arduino Mangoni (Chair), Dr Nicola
Peel and Dr Barbara Gregson (trialist and statistician).
Exit strategy
Participants in this study will discontinue the study sup-
plementation after 12 months of supplementation. They
are then free to use over the counter supplements of
vitamin D.
All clinically relevant findings will be reported to the par-
ticipants’ GPs by the CI (Dr Terry Aspray) who will also
offer advice on clinical management of bone-related health
issues through the Freeman Hospital Musculoskeletal
Unit.
Discussion and potential impact
This study will provide clarification of the dose of vita-
min D required to prevent bone loss in older people in
the UK and will influence the formulation of dietary rec-
ommendations of vitamin D at the population level. This
study is novel and clinically relevant, as it will compare
the effect of three different doses of vitamin D on BMD
and plasma 25OHD, PTH and biochemical markers of
bone turnover in both men and women. This study eval-
uates the effects of vitamin D as mono-therapy rather
than combined with calcium. The data complement
current evidence on the balance of risks in using vitamin
D with or without calcium supplementation [68]. The
study also offers the opportunity to evaluate the impact
of different dosages of vitamin D supplement on struc-
tural (DXA Scanning) and biochemical markers which
allow a better definition of Vitamin D sufficiency for
bone health and to determine an adequate vitamin Dintake to maintain musculoskeletal function. We aim to
develop a set of biochemical markers that reflect the
effect of vitamin D intervention on bone. This will aid
future larger studies investigating the effect of vitamin D
supplementation on fracture risk.
Although the study is primarily powered to detect an
effect of vitamin D supplementation on BMD, it will also
provide data on the effect of vitamin D supplementation
on other functional outcomes, such as quality of life,
physical performance and falls. Further, safety data are
collected and analysed for the effects of the different
dosages, temporal trends and the cumulative dosage. In
addition, this study will provide data on the effect of sea-
son on vitamin D status and other markers and improve
knowledge of the role of monthly (rather than daily)
dosing with vitamin D.
Trial status
The VDOP study commenced recruitment in November
2012; recruitment is scheduled to be completed at end
of June 2013, with follow-up for 12 months thereafter.
Endnotes
aFreeman Hospital, Freeman Road, High Heaton,
Newcastle-upon-Tyne, Tyne and Wear, NE7 7DN, United
Kingdom.
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